Hepatocellular carcinoma and Glossitis

Summary:

Glossitis is found among people with Hepatocellular carcinoma, especially for people who are male, 60+ old.

The study analyzes which people have Glossitis with Hepatocellular carcinoma. It is created by eHealthMe based on reports of 19 people who have Hepatocellular carcinoma from the Food and Drug Administration (FDA), and is updated regularly. You can use the study as a second opinion to make health care decisions.

What is Hepatocellular carcinoma?

Hepatocellular carcinoma (liver cancer) is found to be associated with 306 drugs and 734 conditions by eHealthMe. Check the latest studies of Hepatocellular carcinoma.

What is Glossitis?

Glossitis (infection of tongue with soreness) is found to be associated with 519 drugs and 868 conditions by eHealthMe. Check the latest studies of Glossitis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

19 people who have Hepatocellular Carcinoma and Glossitis are studied.

Would you have Glossitis when you have Hepatocellular carcinoma?

Gender of people who have Hepatocellular Carcinoma and experienced Glossitis *:

female: 36.84 %
male: 63.16 %

Age of people who have Hepatocellular Carcinoma and experienced Glossitis *:

Common co-existing conditions for these people *:

Hyperaesthesia: 2 people, 10.53%
High Blood Pressure: 2 people, 10.53%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 1 person, 5.26%

Common drugs taken by these people *:

Cabometyx: 7 people, 36.84%
Nexavar: 6 people, 31.58%
Lenvima: 2 people, 10.53%
Lenvatinib: 2 people, 10.53%
Amlodipine: 2 people, 10.53%
Zolpidem Tartrate: 1 person, 5.26%
Zoledronic Acid: 1 person, 5.26%
Tecentriq: 1 person, 5.26%
Tamsulosin Hydrochloride: 1 person, 5.26%
Tace: 1 person, 5.26%

Common symptoms for these people *:

Fatigue (feeling of tiredness): 8 people, 42.11%
Weight Decreased: 7 people, 36.84%
Diarrhea: 7 people, 36.84%
Headache (pain in head): 6 people, 31.58%
Stomatitis (inflammation of mucous membrane of mouth): 6 people, 31.58%
Hair Loss: 5 people, 26.32%
Pain In Extremity: 5 people, 26.32%
Palmar-Plantar Erythrodysaesthesia Syndrome (hand-foot syndrome): 5 people, 26.32%
Dry Skin: 5 people, 26.32%
Abdominal Pain: 4 people, 21.05%

* Approximation only. Some reports may have incomplete information.

Do you take medications and have Glossitis?

- Check whether Glossitis is associated with a drug or a condition

Related publications that referenced our studies

Musri FY, Mutlu H, K?vrak Salim D, Karakurt Ery?lmaz M, ?nal B, Tural D, ?enol Co?kun H, "Sorafenib-induced severe urticaria in a patient with hepatocellular cancer", Journal of Oncology Pharmacy Practice, 2016 Jan .
Musri FY, Mutlu H, K?vrak Salim D, Karakurt Ery?lmaz M, ?nal B, Tural D, ?enol Co?kun H, "Sorafenib-induced severe urticaria in a patient with hepatocellular cancer", Journal of Oncology Pharmacy Practice, 2016 Jan .

Related studies:

Treatments, associated drugs and conditions:

Hepatocellular carcinoma (32,153 reports)
Glossitis (5,292 reports)

All the drugs that are associated with Glossitis:

Glossitis (519 drugs)

All the conditions that are associated with Glossitis:

Glossitis (868 conditions)

How the study uses the data?

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

The study is based on Glossitis and Hepatocellular carcinoma, and their synonyms.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.